LncRNA Malat1 represses Th17 effector program by maintaining a critical bivalent super-enhancer and promotes intestinal inflammation
S. Ma, B. Zhou, Y. Abe, N. Chen, C. Luo, Y. Li, P. R. Patel, A. Zheng, S. A. Patel, Y. Hao, J. T. Chang, X. Fu, W. J. M. Huang
Abstract
Interleukin IL-17 cytokines are central regulators of mucosal homeostasis and disease. In mouse models of colonic tissue injury, IL-17A promotes epithelial barrier functions and restricts local inflammation. Here, we report that IL-17A production by the diverse T lymphocyte subsets is dynamically regulated at different stages of colitis pathogenesis. During the onset and peak of the disease, T{gamma}{delta}17 cells are the major IL-17A producers, while Th17 activity is temporally restricted by long non-coding RNA (lncRNA) Malat1. In response to IL-6 and TGF{beta} signaling, Malat1 is recruited to the Th17-specific cis-regulatory elements, CNS3 and CNS4, of the Il17a locus to fine-tune bivalent super-enhancer activities and repress local transcription. During the resolution phase of inflammation, Malat1 expression is down-regulated to enhance Th17 activities, allowing Th17 cells to emerge as the main producers of IL-17A in the colonic lamina propria. Genetic ablation of Malat1 potentiates IL-17A production in Th17 cells and improves disease outcomes in mouse models of colitis. These findings uncover a surprising role of a chromatin-associated lncRNA in regulating colonic Th17-specific responses to control the timing of inflammation resolution. Significance StatementT cells are critical modulators of mucosal barrier function and inflammation. The function of long-noncoding RNAs (lncRNAs) in T cells and their role in mucosal inflammation remain elusive. Here, we identify an essential role of the lncRNA Malat1 restricting transcription of the Il17a locus in Th17 cells encoding a cytokine implicated in epithelial barrier function post-injury. By controlling the activity of the bivalent super-enhancer at the Il17a locus, Malat1 regulates the timing of inflammation resolution in the intestine. The Malat1-Il17a pathway reveals new targets for combating mucosal diseases. Graphic Abstract O_FIG_DISPLAY_L [Figure 1] M_FIG_DISPLAY C_FIG_DISPLAY
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- MAIT cells drive chronic inflammation in a genetically diverse murine model of spontaneous colitis.
Liyen Loh, David J. Orlicky, … Laurent Gapin·Mucosal ImmunologyPeer-reviewed·May 25, 2025
- ADAR2 deaminase activity promotes Th17 effector function and protects against intestine inflammation
S. Ma, Y. Hao, … W. J. M. Huang·bioRxiv·Sep 22, 2020
- Induction of a colitogenic phenotype in Th1 cells depends on IL-23R signaling
M. Pawlak, D. DeTomaso, … V. K. Kuchroo·bioRxiv·Jan 24, 2021
- Selective IL-27 production by intestinal regulatory T cells permits gut-specific regulation of Th17 immunity
- Type I interferon signaling promotes mucosal inflammation in murine models of colitis
Jianyi Yin, Rodrigo Galicia-Pereyra, … Ezra Burstein·bioRxiv·Mar 4, 2026
- DNAM-1 immunoreceptor integrates innate and adaptive immune programs to drive intestinal inflammation
Natsuki Ide, kazuki Sato, … Akira Shibuya·bioRxiv·Apr 1, 2026